After previous public health emergencies likes SARS and H1N1, there was renewed investment in pandemic preparedness, but it was not sustained. We cannot make the same mistake after COVID-19.
In China, the wildlife trade is thriving, driven by the increased demands for luxury goods and traditional medicine. But there is real concern about the threat of diseases that can cross over to humans.
While neoliberalism has allowed U.S. markets to grow, the resultant stunted public health system left Americans to figure out how to protect themselves from COVID-19 and its fallout on their own.
In east Asian countries, past disease outbreaks have made face masks part of everyday life – but the social context supporting such behaviour isn’t present in the UK.
The US was not ready for the coronavirus pandemic in 2020. What can public health leaders and policymakers do to make sure we don’t face another winter of rampant disease?
After SARS in 2003, an effort was made by Toronto’s tourism and hospitality industries to stimulate the sector’s recovery. But measures weren’t put in place for future pandemics.
As ready as you are to be done with COVID-19, it’s not going anywhere soon. A historian of disease describes how once a pathogen emerges, it’s usually here to stay.
A new study is the first to identify sex differences in inflammation and immune cell activation in response to SARS-CoV-2 infection, which causes COVID-19.
Our first exposure to a pathogen, either naturally or via vaccination, can affect how our immune system responds in the future to the same or similar pathogens.
COVID-19 tests rely on a process developed at a biotech company co-founded by a Canadian. Canada’s current testing expertise needs to be channelled to prepare for the next wave, and the next pandemic.
Australia’s island identity and attitude to border security was forged from handling pandemics since the time of federation. Here’s what we’ve learned along the way.
During the last six months, news reports have mentioned dozens of drugs that may be effective against the new coronavirus. Here we lay out the evidence and reveal which ones are proven to work. Or not.
The virus that caused the original Sars no longer haunts us, but the characteristics of today’s coronavirus mean it’s unlikely to disappear in the same way.
Results from phase 1 trials of a COVID-19 mRNA vaccine created a burst of optimism. But details the company failed to release suggest it is too early to speculate whether the vaccine is effective.